Sarepta Therapeutics’ (SRPT) Sell Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Tuesday,Benzinga reports.

A number of other equities analysts have also weighed in on SRPT. Barclays cut their price objective on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 5th. Bank of America raised their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a report on Wednesday, October 22nd. Piper Sandler increased their target price on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Wedbush increased their price target on Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Finally, Guggenheim cut their price target on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Trading Down 2.8%

NASDAQ:SRPT opened at $22.17 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The stock has a fifty day simple moving average of $21.32 and a 200-day simple moving average of $19.86. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $120.05. The company has a market capitalization of $2.32 billion, a PE ratio of -7.37, a price-to-earnings-growth ratio of 0.56 and a beta of 0.48.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same quarter in the previous year, the firm posted $0.62 EPS. The business’s revenue was down 14.5% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SRPT. AQR Capital Management LLC grew its position in Sarepta Therapeutics by 214.2% in the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after buying an additional 3,671 shares during the last quarter. Great Lakes Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at $224,000. Public Employees Retirement System of Ohio grew its stake in Sarepta Therapeutics by 2.2% in the second quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock valued at $492,000 after purchasing an additional 607 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Sarepta Therapeutics by 123.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 15,882 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. grew its position in Sarepta Therapeutics by 5,166.3% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 105,326 shares of the biotechnology company’s stock worth $1,801,000 after acquiring an additional 103,326 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company press release and coverage report ELEVIDYS produced statistically significant, clinically meaningful slowing of Duchenne progression at three years in the EMBARK Phase 3 topline results, driving investor optimism about the therapy’s commercial prospects. Sarepta Announces Positive Topline Three-Year EMBARK Results
• Positive Sentiment: Market reaction included an intraday jump noted by Zacks as shares climbed after the long‑term Elevidys data showed sustained motor gains and slower progression at three years. SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
• Positive Sentiment: Major outlets (Reuters, Barron’s, Proactive) reinforced the data’s credibility with independent reporting of the three‑year benefits, supporting near‑term sentiment and potential uptake. Reuters: Sarepta’s Duchenne gene therapy helps maintain motor function
• Positive Sentiment: Zacks upgraded SRPT to a Buy, signaling growing optimism from some sell‑side analysts that the data improves earnings prospects and valuation upside. Sarepta Therapeutics (SRPT) Upgraded to Buy
• Neutral Sentiment: Seeking Alpha published slides and a transcript of Sarepta’s EMBARK presentation — useful for investors wanting the detailed endpoints, subgroup analyses and methodology. Seeking Alpha: EMBARK 3‑Year Results Slides/Transcript
• Neutral Sentiment: Analysts and outlets are reassessing SRPT valuation after the short‑term momentum; a Yahoo Finance piece looks at valuation upside versus remaining uncertainties. Assessing Sarepta Therapeutics (SRPT) Valuation
• Negative Sentiment: Citi (reported via TipRanks) reiterated a bearish stance, citing safety uncertainty and label risk that they say overshadow the positive Elevidys data and support a Sell/high‑risk rating. TipRanks: Safety Uncertainty and Label Risk Overshadow Elevidys Data
• Negative Sentiment: HC Wainwright reaffirmed a Sell rating (reported by Benzinga), signaling that at least some sell‑side firms remain unconvinced and could pressure sentiment. Benzinga: HC Wainwright Reaffirms Sell
• Negative Sentiment: Pre‑existing safety concerns remain relevant: prior FDA restrictions on ELEVIDYS (after liver‑related adverse events in non‑ambulatory patients) are cited in coverage and underpin continued label and commercial risk. Blockonomi: Investors Brace for Pivotal Data; FDA Restriction Context

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.